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ABSTRACT
Background and objectives: To assess frequency and signifi-
cance of enlarged nonpalpable supraclavicular lymph nodes
with routine ultrasound (US) evaluation and US-guided fine-
needle aspiration biopsy (FNAB) for the diagnosis and staging
of patients with lung cancer.
Materials and methods: 106 consecutive patients with lung
cancer and nonpalpable supraclavicular lymph nodes were
evaluated with cervical US for the presence of pathological
lymph nodes. FNAB was performed in patients with nodes
with short-axis > 5 mm, rounded shape and missing
echogenic hilum. 
Results: 27 (25.5%) patients had enlarged supraclavicular
lymph nodes on US. Fourteen patients (13.2%) had cytologi-
cally proven lymph node involvement. Supraclavicular lymph
node metastasis was more frequent in patients with medi-
astinal invasion (p = 0.0001) and patients with enlarged
lymph nodes on upper paratracheal stations on thorax CT 
(p = 0.0001). No relation was found between supraclavicular
lymph node involvement and T stage (p = 0.27), distant
metastasis (p = 0.50) or histological type (p = 0.80). Three
patients were upstaged from IIIA to IIIB status. US-guided
FNAB was the only diagnostic method in 2 patients. 
Conclusion: US-guided FNAB is a simple and safe procedure
which can document N3 stage of disease in lung cancer
patients. Thereby more invasive and expensive diagnostic
procedures can be avoided in selected lung cancer patients. 
Keywords: Diagnosis, fine-needle aspiration biopsy, lung can-
cer, staging, ultrasonography.
RIASSUNTO 
Razionale ed obiettivi: Valutare la frequenza e la rilevanza di
linfonodi sopraclaveari di dimensioni aumentate, ma non pal-
pabili, mediante una valutazione routinaria con ultrasuoni
(US) ed una biopsia mediante agoaspirato con ago sottile
(FNAB) sotto guida US per la diagnosi e la stadiazione dei pa-
zienti con tumore polmonare.
Materiali e metodi: 106 pazienti consecutivi con cancro del
polmone e linfonodi sopraclaveari non palpabili sono stati in-
dagati con US cervicali per valutare la presenza di linfonodi
patologici. Nei pazienti con linfonodi aventi asse minore > 5
mm, forma arrotondata ed ilo non evidenziabile ecografica-
mente è stata praticata la FNAB.
Risultati: 27 (25,5%) pazienti avevano linfonodi sopraclaveari
di dimensioni aumentate all’indagine US. 14 pazienti (13,2%)
sono risultati positivi alla citologia sull’agoaspirato. Le meta-
stasi ai linfonodi sopraclaveari sono risultate più frequenti nei
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pazienti con interessamento del mediastino (p = 0,0001) e
nei pazienti che alla TAC torace mostravano un ingrandimen-
to delle stazioni linfonodali paratracheali superiori 
(p = 0,0001). Non sono state riscontrate correlazioni tra l’in-
teressamento dei linfonodi sopraclaveari e stadio T (p = 0,27),
metastasi a distanza (p = 0,50) o istotipo (p = 0,80). Tre pa-
zienti sono stati allocati ad una stadiazione peggiore, da IIIA a
IIIB. In 2 pazienti la FNAB US-guidata è risultata l’unica meto-
dica che ha permesso la diagnosi.
Conclusioni: La FNAB US-guidata è una procedura semplice e
sicura che permette di documentare lo stadio N3 in pazienti
con cancro polmonare. Quindi procedure diagnostiche più in-
vasive e dispendiose possono essere evitate in pazienti sele-
zionati con tumore polmonare.
Parole chiave: Biopsia mediante agoaspirato, diagnosi, stadia-
zione, tumore polmonare, ultrasuoni.    
INTRODUCTION
It is estimated that about one million people die in
the world every year due to lung cancer [1]. Tumor
stage is the foremost factor that affects prognosis of
lung cancer. About 49% of lung cancer cases have
distant metastasis on admission. In a revision of the
international system for staging lung cancer it was
reported that 86% of lung cancer patients were in
the advanced stage [2]. 
During the last 20 years, the most important devel-
opment in lung cancer has probably been the deter-
mination of cases eligible for surgical treatment by
staging systems. In staging, the fundamental strategy
is to diagnose and stage cases with a simple and fast
method and refer them to appropriate treatment
modalities. Detection of lymph node metastasis in
the supraclavicular region can guide the treatment
by indicating N3 lymph node metastasis (stage IIIB
status, i.e. inoperable) and so prevent unnecessary
surgery. Since the procedure caters for both diagno-
sis and staging at the same time, unnecessary inva-
sive diagnostic procedures might be avoided as
well.
MATERIALS AND METHODS
This was a prospective study that consecutively en-
rolled patients with lung cancer, who were recruit-
ed from inpatient services and outpatient referrals
from non-specialized physicians. The inclusion cri-
teria for the patients were the presence of lung can-
cer with nonpalpable supraclavicular lymph nodes
and no prior diagnosis of malignancy. Patients were
excluded before further evaluation with ultrasound-
guided fine-needle aspiration biopsy (FNAB) if the
diagnosis was not lung cancer. Positron emission to-
mography (PET) scan was not able to be performed
for the purpose of evaluation of mediastinal and
supraclavicular lymph nodes. Ultrasound (US) ex-
amination was made by the same radiologist. US
was performed using a 5-7.5 MHz linear probe on
a Shimadzu SDV-450 machine. Examination was
limited to a B scan and no Doppler imaging was
conducted. Transverse and sagittal images were ob-
tained from the carotid bifurcation to the stern-
oclavicular area inferior and lateral to the acromio-
clavicular joint. The number and location of the en-
larged lymph nodes, including whether they were
ipsilateral, contralateral, or bilateral with respect to
the dominant lung lesion, and their short- and long-
axis were documented. The lymph node was classi-
fied as pathological if the short axis was > 5 mm, no
echogenicity was detected on the hilus of the lymph
node, and the long axis/short axis ratio was < 2
(rounded shape). 
US-guided FNAB procedures were performed by 2
pulmonologists. The patients were placed in a
supine position with the neck hyperextended.
Enlarged nodes were aspirated with fine 20 gauge
needles. Cytological examination results were
recorded. Since supraclavicular US examination is
a non-invasive procedure and FNAB was performed
on enlarged lymph nodes, as recommended by
guidelines, we asked all patients simply to sign an
informed consent before enrolling in the study. 
Chi-square and McNemar tests were used for statis-
tical analysis.
RESULTS
A total of 136 patients with suspected lung cancer
were recruited for the study. Twenty-eight patients
were excluded due to lack of definitive cancer diag-
nosis or a final diagnosis other than cancer. FNAB
was not performed because of close proximity of
supraclavicular lymph nodes to the vascular struc-
tures in 2 patients; these patients were also exclud-
ed from the study. Finally 106 patients were eligible
for the study. 
Mean age of the patients was 59.4 years. Seven
(6.6%) of the patients were female and 99 (93.4%)
were male. Demographic and clinical characteris-
tics of the patients are shown in Table I. 
Twenty-five (23.6%) patients had morphologically
pathological supraclavicular lymph nodes at US.
Fourteen patients (13.2%) had cytologically con-
firmed supraclavicular lymph node metastasis. An
association was found between the presence of
supraclavicular lymph node invasion and presence
of lymph nodes in 2R-2L stations on thorax CT 
(p = 0.03), ≥ N2 nodal stage (p = 0.001), central lo-
cation of tumor (p = 0.03), and radiological presence
of mediastinal invasion (p = 0.01). There was no re-
lation between the supraclavicular lymph node inva-
sion and histological type of tumor (p = 0.80), T stage
(p = 0.27) or M stage (p = 0.50) (Table II). 
There was no correlation between the number and
size of supraclavicular lymph nodes at US and
lymph node involvement (Table III). Three patients
(2.8%) were upstaged to inoperable stage IIIB from
operable stage IIIA by US-guided supraclavicular
lymph node FNAB. Before US-guided FNAB, 37 pa-
tients were considered as surgery candidates, 69
patients were considered for chemotherapy and/or
radiotherapy. After US-guided FNAB examination
the number of surgery candidates decreased to 34
patients. But statistically no significant difference































in regard to treatment (p = 0.25). 
US-guided FNAB was the sole diagnostic method in
2 patients (1.9%) with distant metastasis. One of
these 2 patients’ diagnosis was a challenge, since
no diagnosis could be established despite the use of
various invasive diagnostic procedures. The other
patient was in a poor health status, and no invasive
procedure could be performed. 
DISCUSSION
Currently, there exist many invasive and non-inva-
sive diagnostic modalities for the diagnosis of lung
cancer. Since staging is the most important prognos-
tic factor in lung cancer, it would be appropriate to
say that diagnostic methods which also provide
staging simultaneously will have an increasing im-
portance in the future. The most important advan-
tage of US-guided FNAB of supraclavicular lymph
nodes is that it allows both diagnosis and staging to
be performed by a single procedure. 
Until recently, supraclavicular lymph nodes were
evaluated by palpation and patients without palpa-
ble lymph nodes were considered as not having
malignant disease. However, during the last 20
years, studies focused on head-neck carcinomas,
esophageal carcinomas, and melanomas have
found palpation of supraclavicular and head re-
gions to be not very reliable for detection of lymph
node metastasis, while noninvasive imaging modal-
ities such as CT and US have been reported to be
more sensitive than palpation [5-8].
Surgical biopsy results of nonpalpable supra -
clavicular lymph nodes are not very sensitive and
only 8.9% of them are reported to detect metastasis
[9]. Haber et al. reported the sensitivity and speci-
ficity of palpation as 64% and 85% respectively,
whereas sensitivity and specificity of supraclavicu-
lar ultrasound was reported to be higher (72% and
96%, respectively) in head and neck cancer pa-
tients [10]. Sensitivity and specificity could not be
evaluated in the present study since no lymph node
TABLE I: CLINICAL CHARACTERISTICS OF THE PATIENTS    
Supraclavicular lymph node Supraclavicular lymph node Total
metastasis (+) metastasis (-)
(n = 14) (n = 92) (n = 106)
Age (years) 56.1 ± 6 59.8 ± 10 59.4 ± 11
Sex (male/female) 13/1 86/6 99/7
I - 2 2
Stage II - 28 28
III 8 31 39
IV 6 31 37
TABLE II: FACTORS ASSOCIATED WITH SUPRACLAVICULAR LYMPH NODE METASTASIS    
Supraclavicular lymph node Supraclavicular lymph node p
metastasis (+) metastasis (-)
(n = 14) (n = 92)




Mediastinal invasion Present 10 33 0.01
Absent 4 59
Nodal staging cN (0 or 1) 0 42 0.00
cN (2 or 3) 14 50
Distant Metastasis Absent 8 61 0.50
Present 6 31
Type of tumor NSCLC 12 81 0.80
SCLC 2 11
Localization of primary tumor Central 13 60 0.03
Peripheral 1 32
Enlarged lymph nodes in 2R-2L Present 12 16 0.00
stations Absent 2 76 0.00
Definition of abbreviations: cN, clinical nodal staging; cT, clinical tumoral staging; 2L, left upper paratracheal lymph node; 2R, right upper
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biopsy was performed in our study. 
Kumaran et al. found the rate of nonpalpable supr-
aclavicular lymph node metastasis higher in cases
with N3 or multiple N2 on thorax CT. Sixty-one
(60%) of their 101 examined cases were subjected
to FNAB with supraclavicular US, and lymph node
metastasis was detected in a total of 46 (45.5%) pa-
tients (at first examination in 44 cases and at second
examination in 2 more cases). Since each patient
first underwent supraclavicular US, unnecessary in-
vasive procedures were eliminated in 43 cases
(42.6%) [11]. Ohno et al. recently published a study
in which they performed mediastinoscopy and supra-
clavicular lymph node biopsy on 123 non-small
cell lung carcinoma patients with nonpalpable
supraclavicular LAM, and found supraclavicular
metastasis in 5 (4.1%) and mediastinal involvement
in 23 (18.7%) cases, while reporting a high rate of
supraclavicular metastasis among patients with
bulky N2 involvement [12]. Ohno et al. and
Kumaran et al. noted a higher likelihood of supra-
clavicular lymph node metastasis among patients
with multiple N2 than others [11,12]. Similarly, in
our study, supraclavicular lymph node invasion
prevalence was higher among those who had en-
larged N2 and N3 on thorax CT (p < 0.001). Sihoe
et al. analyzed 50 cases suspected of potentially re-
sectable lung cancer. Supraclavicular US revealed
lymph nodes suggestive of malignancy in 10 (20%)
of 50 cases, cervical lymph node metastasis was de-
termined in 4 (8%), and further invasive diagnostic
methods were deemed unnecessary because 2 of
those cases advanced to stage IIIB. The authors ad-
vocated use of this technique in routine preopera-
tive evaluation as a cost-effective treatment man-
agement due to the possibility it allows to avoid un-
necessary surgery [9]. 
In our study, the cases in the supraclavicular lymph
node metastasis group were generally at advanced
stages; at the time of diagnosis, 3 (21.4%) cases
were at stage IIIA and the remaining 11 (78.6%)
were at stage IIIB or IV. Three of those patients ad-
vanced to stage IIIB from IIIA. Change from stage 
IIIA to IIIB may appear to be minimal, but costly im-
aging modalities to evaluate surgical respectability,
including fluorodeoxyglucose positron emission to-
mography (FDG-PET) and magnetic resonance (MR)
as well as invasive diagnostic and staging tech-
niques including mediastinoscopy, video-assisted
thoracic surgery (VATS), and mediastinostomy were
avoided. 
Overhagen et al. compared palpation, cervical CT,
thoracic CT and supraclavicular US in 117 lung
cancer patients and showed supraclavicular meta -
stasis in 30 (26%) patients. They determined supra-
clavicular lymph node metastasis in 8 (31%) of 26
SCLC cases and in 22 (24%) of 91 NSCLC cases.
Sensitivity of supraclavicular US, CT, and palpation
in lymph node detection were 100%, 83%, and
33% respectively; supraclavicular US and CT
modalities were found to be significantly more sen-
sitive than palpation [5]. 
Fultz et al. compared CT and supraclavicular US in
potentially operable lung cancer cases without pal-
pable supraclavicular lymph node, and determined
supraclavicular lymph node metastasis in 17 (31%)
of 55 cases. While supraclavicular US demonstrat-
ed lymph node in 22 (40%) of the cases, CT re-
vealed lymph nodes only in 18 (33%) cases.
Supraclavicular US may display some supraclavicu-
lar lymph nodes that do not appear distinct on CT.
They reported supraclavicular lymph node metasta-
sis in 46% of cases with enlarged mediastinal
lymph nodes and 48% of cases with suspected dis-
tant metastasis. Thus they suggested that supraclavic-
ular lymph node metastasis could be as frequent as
distant extrapulmonary metastases [13]. 
Chang et al. determined the prevalence of SC
lymph node metastasis as 12% in 51 patients and
the majority of the cases had centrally located tu-
mors [15]. In the current study, 68.5% of the cases
had centrally located tumor, and the frequency of
supraclavicular lymph node involvement was high-
er in those cases (p < 0.05). Similarly patients with
mediastinal invasion on CT had a higher rate of
supraclavicular lymph node involvement (p < 0.05). 
Ozkan et al. performed a similar study on 40 lung
cancer patients who had multiple mediastinal 
lymphadenomegaly on thorax CT, and detected
supraclavicular lymph node invasion in 16 (40%)
patients [16]. In this study, supraclavicular lymph
node invasion was more frequent among patients
with enlarged upper paratracheal lymph nodes on
CT. US-guided FNAB was the sole diagnostic
method in 2 patients and 3 patients advanced to
stage IIIB. US-guided FNAB did not change the ther-
apeutic approach of the study population. In the
present study, 28 (26%) of the cases had enlarged
lymph nodes in 2R-2L stations on CT. Twelve pa-
tients (86%) with supraclavicular lymph node
metastasis had lymph nodes of pathological size in
2R-2L stations. Among those cases, the frequency of
TABLE III: RELATIONSHIP BETWEEN SUPRACLAVICULAR LYMPH NODE INVOLVEMENT AND SUPRACLAVICULAR LYMPH NODE
SIZE AND NUMBER     
Supraclavicular lymph node Supraclavicular lymph node p
metastasis (+) metastasis (-) 
Supraclavicular lymph node size ≥ 1 cm 10 5 0.24
< 1 cm 4 6































5 lymph node detection and positivity of FNAB were
found to be higher (p = 0.0001). 
In our study, 37 (35%) patients had clinical and ra-
diological finding of metastasis, 30% of those were
extrapulmonary distant organ metastasis. Six of 37
stage IV patients (16%) had supraclavicular lymph
node metastasis. Ozkan et al. reported that 6 of 10
stage IV patients (60%) had supraclavicular lymph
node metastasis. While supraclavicular US-guided
FNAB does not contribute much to staging in patients
with stage IV, it seems valuable in terms of being a
simple and less invasive method for diagnosis [14]. 
US-guided FNAB may rarely lead to some compli-
cations such as hemorrhage, infection, pneumo-
thorax, lymph channel damage, air embolism,
phrenic nerve damage, and recurrent laryngeal
nerve damage [12,17,18]. No complications have
been observed in studies involving US-guided
FNAB of the supraclavicular region, suggesting US-
guided FNAB as a safe method [5,11,13,19].
Limitations of our study
US examination was limited to B-mode. The US de-
vice we used had no Doppler option. Doppler al-
lows a better distinction of lesions of vascular origin
and enables visualization of the blood flow pattern
in lymph nodes suspected of malignancy. Although
supraclavicular pathological lymph nodes were ob-
served in 25 patients by US, cytological verification
was achieved in 14 patients by performing FNAB
once. Among those patients, the lymph nodes de-
tected by US may be mistaken as being benign. A
second FNAB performed on morphologically
pathological but cytologically negative supra-
clavicular lymph nodes might provide more reliable
results. Moreover, the “gold standard” lymph node
excision was not applied; thus sensitivity, specifici-
ty, true positivity, and true negativity rates could not
be calculated. 
CONCLUSION
We believe that using supraclavicular US-guided
FNAB as a routine initial screening and diagnosis
test on admission of all cases of suspected lung can-
cer may not be very helpful. Nonetheless, it may be
performed as the initial examination method in cas-
es with: advanced stage of lung cancer; problematic
diagnosis; limited respiratory function and/or poor
overall health status; presence of mediastinal lymph
nodes, particularly the upper paratracheal lymph
node, on thorax CT; and centrally located tumors
invading the mediastinum. In cases where malig-
nancy is diagnosed by US-guided FNAB, unneces-
sary invasive diagnostic methods can be avoided. It
is a safe and simple method for selected patients
which allows diagnosis and staging in a single step. 
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